WO2019241910A1 - 基于药物预处理的间充质干细胞来源外泌体的制备方法 - Google Patents

基于药物预处理的间充质干细胞来源外泌体的制备方法 Download PDF

Info

Publication number
WO2019241910A1
WO2019241910A1 PCT/CN2018/091843 CN2018091843W WO2019241910A1 WO 2019241910 A1 WO2019241910 A1 WO 2019241910A1 CN 2018091843 W CN2018091843 W CN 2018091843W WO 2019241910 A1 WO2019241910 A1 WO 2019241910A1
Authority
WO
WIPO (PCT)
Prior art keywords
mesenchymal stem
stem cells
exosomes
atv
statins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/091843
Other languages
English (en)
French (fr)
Inventor
杨跃进
黄沛森
陈桂浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuwai Hospital of CAMS and PUMC
Original Assignee
Fuwai Hospital of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuwai Hospital of CAMS and PUMC filed Critical Fuwai Hospital of CAMS and PUMC
Priority to JP2019554538A priority Critical patent/JP6825182B2/ja
Priority to KR1020197033974A priority patent/KR102235141B1/ko
Priority to PCT/CN2018/091843 priority patent/WO2019241910A1/zh
Priority to EP18923225.9A priority patent/EP3663394B1/en
Publication of WO2019241910A1 publication Critical patent/WO2019241910A1/zh
Priority to US16/833,405 priority patent/US20200224169A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Definitions

  • the invention relates to a method for preparing mesenchymal stem cell-derived exosomes based on drug pretreatment, in particular to a method for preparing high-efficiency mesenchymal stem cell-derived exosomes based on statin pretreatment.
  • AMI Acute myocardial infarction
  • MSCs mesenchymal stem cells
  • BM-MSCs bone marrow-mesenchymal stem cells
  • Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410 (6829): 701-705; Fisher SA, Doree, C, Mathur A, Martin-Rendon E. Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure Circulation Research 2015; 116 (8): 1361-1377; Afzal MR, Samanta A, Shah ZI, Jeevanantham V Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials. CircRes 2015; 117 (6): 558-575).
  • mesenchymal stem cells can improve cardiac function after infarction to some extent through paracrine protection, the effect is not significant. Further research shows that the main mechanism for its paracrine protection is achieved by secreting an extracellular vesicle structure, exosome (Makridakis M, Roubelakis MG, Vlahou A. Stem cells: insights into the secrete .Biochim Biophys Acta 2013; 1834 (11): 2380-2384; Huang P, Tian X, Li Q, Yang Y. New strategies for cell improvement therapy in heart ischemic heart heart disease.
  • Exosome Secreted by MSC reduces myocardial Res 2010; 4 (3): 214-222). Exosomes have the advantages of wide sources, stability, and non-immunogenicity, and BM-MSCs-derived exosomes (MSC-Exo) can improve the microenvironment of myocardial infarction.
  • An object of the present invention is to provide a method for preparing exosomes derived from highly effective mesenchymal stem cells.
  • statins such as Atorvastatin (ATV) pre-treated mesenchymal stem cells can significantly improve the anti-apoptotic ability and homing ability of mesenchymal stem cells, and have a significant myocardial infarction. Stem cell-derived exosomes with microenvironment improvement and highly efficient myocardial repair.
  • ATV Atorvastatin
  • the present invention provides a method for preparing mesenchymal stem cell-derived exosomes.
  • the method includes: pre-treating mesenchymal stem cells with statins, and culturing the treated mesenchymal stem cells to collect secreted mesenchymal stem cells. Exosomes.
  • a method for preparing mesenchymal stem cell-derived exosomes of the present invention includes:
  • the cell culture medium After adding statins to the mesenchymal stem cell culture medium for pretreatment for 12-24 hours, the cell culture medium was replaced with a complete medium without exosomes to continue the cultivation; after 48 hours, the conditioned medium was collected and separated by ultracentrifugation Exosomes secreted by mesenchymal stem cells were obtained by pretreatment with statins.
  • the ultracentrifugation method includes the steps:
  • centrifuge After collecting conditioned medium, centrifuge in order to remove cells, centrifuge to remove cell debris, high-speed centrifugation to remove large vesicles, and then collect the pellet by ultracentrifugation and resuspend, and then obtain the exosomes by ultracentrifugation again;
  • the cells are centrifuged at 300g for 10 minutes to remove the cells; the cells are centrifuged at 2000g for 20 minutes to remove cell debris; the 16500g is centrifuged at high speed for 30 minutes to remove large vesicles; and the pellets are collected after 120,000 g ultracentrifugation for 70 minutes and resuspended. Exosomes were obtained by ultracentrifugation at 120,000 g for 70 min.
  • the statin in the method for preparing mesenchymal stem cell-derived exosomes of the present invention, includes atorvastatin.
  • the mesenchymal stem cells include bone marrow mesenchymal stem cells or adipose mesenchymal stem cells.
  • the present invention also provides exosomes prepared according to the method of the present invention.
  • the present invention also provides the application of statins in the preparation for promoting the anti-apoptotic ability and / or the homing-promoting ability of mesenchymal stem cells.
  • the present invention also provides the application of statins in the preparation of exosomes which promote the secretion of mesenchymal stem cells and have the effect of improving the microenvironment of myocardial infarction and / or the ability of myocardial repair.
  • the statin includes atorvastatin; preferably, the mesenchymal stem cells are pretreated with 1 ⁇ M statin for 24 hours.
  • the mesenchymal stem cells include bone marrow mesenchymal stem cells or adipose mesenchymal stem cells.
  • exosomes with high-efficiency myocardial repair and endothelial protection can be obtained by pre-treating BM-MSC with 1 ⁇ M ATV for 24 hours.
  • 1A-1C show the results of identification of exosomes derived from mesenchymal stem cells according to the embodiment of the present invention.
  • Figures 2A-2D show the effect of exosomes derived from mesenchymal stem cell pretreatment on endothelial cells with different concentrations of ATV.
  • 3A-3H show the results of ATV pretreatment of mesenchymal stem cell-derived exosomes to promote tube formation, migration, and survival of vascular endothelial cells.
  • Figures 4A-4F show the results of detection of mesenchymal stem cell-derived exosomes pretreated with ATV, which can significantly improve cardiac function and reduce the infarcted area after myocardial infarction in rats.
  • 5A-5K show the detection results related to the protective effect of mesenchymal stem cell-derived exosomes and their upregulation of lncRNAH19 after ATV pretreatment.
  • BM-MSCs Primary rat (Sprague-Dawley rat, 60-80g) BM-MSCs were isolated by differential adherence and passaged to 3-4 generations for future use. After adding ATV pretreatment to BM-MSCs complete medium (IMDM, Invitrogen, USA) for 24 hours, the cell culture medium was replaced with exosomes-free complete medium (containing 10% FBSIMDM after 18 hours of ultracentrifugation) Continue training. After 48 hours, the conditioned medium was collected and separated by ultracentrifugation to obtain exosomes (MSC ATV- Exo) secreted by BM-MSCs pretreated by ATV.
  • IMDM Invitrogen, USA
  • the specific steps of ultracentrifugation include: centrifuging 300g for 10min to remove cells after collecting conditioned medium; 2000g centrifuging for 20min to remove cell debris; 16500g high-speed centrifugation for 30min to remove large vesicles; 120,000g ultracentrifugation for 70min to collect the precipitate and resuspend, and then 120000g ultracentrifugation for 70min Obtain exosomes.
  • MSC ATV- Exo The effects of different concentrations of ATV pretreatment on the function of MSC ATV- Exo were compared, and the optimal ATV pretreatment concentration was screened.
  • Functional evaluation of MSC ATV- Exo prepared using this optimal ATV concentration for pretreatment includes effects on tube formation, migration, and anti-apoptotic effects of vascular endothelial cells and improvement of cardiac function in rats after myocardial infarction after intramyocardial injection, The effect of reducing infarct size.
  • molecular evaluation was performed, that is, detection of lncRNA H19 expression level in MSC ATV- Exo.
  • the MSC ATV- Exo separated by ultracentrifugation showed a spherical or disc shape under the electron microscope with a size of about 100 nm; its particle size distribution was in the range of 30-150 nm by NTA analysis; Western Blot detection showed that MSC ATV- Exo highly expressed TSG101 , Alix, CD63, CD81 and other exosomal protein markers. There were no significant differences in morphology, particle size distribution, and protein markers between exosomes secreted by BM-MSC and ATV pretreatment. The specific results can be seen in FIG. 1A to FIG. 1C, wherein FIG.
  • FIG. 1A Observing the morphological structure of mesenchymal stem cell-derived exosomes (MSC-Exo) under an electron microscope, which is spherical or disc-shaped, with a size of about 100 nm, which is pre-stated by statins The morphology does not change after treatment;
  • Figure 1B Analysis of the particle size distribution of MSC-Exo by NTA. The particle size distribution of statin pretreated and untreated MSC-Exo are in the range of 30-150nm;
  • Figure 1C protein of exosomes Marker identification, statin-pretreated MSC-Exo overexpressed TSG101, Alix, CD63, CD81 and other exosomal protein markers.
  • FIGS. 2A-2D Functional analysis of MSC ATV- Exo pretreated by different concentrations of ATV (0.01, 0.1, 1, 10 ⁇ M) pre-treatment revealed that MSC ATV- Exo pretreated with 1 ⁇ M ATV pretreatment had the most significant effect on promoting endothelial cell tube formation and migration. .
  • FIGS. 2A-2D For specific results, please refer to FIGS. 2A-2D.
  • Figures 2A-B Comparison of the effects of exosomes extracted from mesenchymal stem cells pretreated with different concentrations of ATV (0.01, 0.1, 1, 10 ⁇ M) on endothelial cell tube formation, with 1 ⁇ MATV being the best.
  • Fig. 2B Fig. 2C-Fig. 2D: Comparison of the effects of exosomes extracted from mesenchymal stem cells pretreated with different concentrations on endothelial cell migration, among which 1 ⁇ M ATV had the best effect (Fig. 2D).
  • MSC ATV -Exo can significantly promote tube formation and migration of vascular endothelial cells, and can promote the survival and anti-apoptotic effects of endothelial cells under hypoxic serum-free conditions.
  • FIG. 3A to FIG. 3H in which FIG. 3A to FIG.
  • FIG. 3B tube formation test, compared with the control group, ATV pretreated mesenchymal stem cell-derived exosomes (MSC ATV- Exo) significantly promoted vascular endothelial cells Tube formation;
  • Figure 3C- Figure 3D Scratch test, compared with the control group, MSC ATV- Exo significantly promoted vascular endothelial cell migration;
  • Figure 3E- Figure 3F Flow cytometry test, compared with the control group, MSC ATV -Exo significantly promoted the survival of vascular endothelial cells under hypoxic and serum-free conditions;
  • Figure 3G- Figure 3H Hoechst 33342 staining.
  • MSC ATV- Exo significantly reduced the vascular endothelial cells under hypoxic and serum-free conditions. Apoptosis.
  • FIGS. 4A to 4F wherein FIGS. 4A to 4B: ATV pretreated mesenchymal stem cell-derived exosomes (MSC ATV- Exo) transplantation significantly improves myocardial function in myocardial infarction rats; FIGS.
  • MSC ATV -Exo highly expressed lncRNA H19, which was more than 10 times.
  • MSC ATV (Si) -Exo small interfering RNA to knock down the expression level of lncRNA H19 in ATV-pretreated MSC and then extract its secreted exosomes (MSC ATV (Si) -Exo)
  • the above protective effect is eliminated, indicating that lncRNA H19 and MSC ATV- Exo are highly efficient
  • the protective effect of endothelial cells, the improvement of cardiac function and the effect of reducing the infarct size please refer to FIG. 5A to FIG. 5K, wherein FIGS.
  • 5A to 5B ATV pretreated mesenchymal stem cell-derived exosomes (MSC ATV- Exo) highly express lncRNA H19, and use small interfering RNA to knock down exosomes (MSC ATV (Si) -Exo) significantly reduced lncRNA H19 expression levels;
  • Figure 5C- Figure 5H Compared with MSC ATV- Exo, MSC ATV (Si) -Exo's endothelial protection was weakened;
  • Figure 5I- Figure 5K Compared with MSC ATV- Exo, MSC ATV ( Si) -Exo improves the cardiac function and myocardial repair after infarction.
  • CONCLUSION Pretreatment of BM-MSC with 1 ⁇ M ATV for 24 hours can obtain exosomes with efficient endothelial protection and myocardial repair. The mechanism is related to up-regulation of lncRNAH19 levels in exosomes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种基于药物预处理的间充质干细胞来源外泌体的制备方法。间充质干细胞来源外泌体的制备方法包括：采用他汀类药物预处理间充质干细胞，并培养处理后的间充质干细胞以收集其分泌的外泌体。还提供了他汀类药物在制备促进间充质干细胞的抗凋亡能力和/或促归巢能力的制剂中的应用，还提供了他汀类药物在制备促进间充质干细胞分泌具有心梗微环境改善作用和/或心肌修复能力的外泌体的制剂中的应用。

Description

基于药物预处理的间充质干细胞来源外泌体的制备方法 技术领域
本发明是关于一种基于药物预处理的间充质干细胞来源外泌体的制备方法，具体是关于一种基于他汀类药物预处理的高效间充质干细胞来源外泌体的制备方法。
背景技术
WHO统计数据表明：2016年心血管疾病是全球第一大死因(约1760万人，32.2％)，其中有948万人死于缺血性心脏病(17.3％)(Collaborators GM.Global,regional,and national under-5 mortality,adult mortality,age-specific mortality,and life expectancy,1970–2016:a systematic analysis for the Global Burden of Disease Study 2016.The Lancet 2017；390(10100):1084-1150；Collaborators GCOD.Global,regional,and national age-sex specific mortality for 264 causes of death,1980–2016:a systematic analysis for the Global Burden of Disease Study 2016.The Lancet 2017；390(10100):1151-1210)。急性心肌梗死(acute myocardial infarction,AMI)导致大量心肌缺血坏死，继而被瘢痕组织替代引发心衰和死亡。现有治疗手段无法有效再生和修复心肌。近年来干细胞移植治疗，尤其是间充质干细胞(MSCs,mesenchymal stem cells)，例如骨髓间充质干细胞(bone marrow-mesenchymal stem cells,BM-MSCs)，移植治疗AMI被寄予厚望(Orlic D,Kajstura J,Chimenti S,Jakoniuk I,Anderson SM,Li B,Pickel J,McKay R,Nadal-Ginard B,Bodine DM and others.Bone marrow cells regenerate infarcted myocardium.Nature 2001；410(6829):701-705；Fisher SA,Doree C,Mathur A,Martin-Rendon E.Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure.Circulation Research2015；116(8):1361-1377；Afzal MR,Samanta A,Shah ZI,Jeevanantham V,Abdel-Latif A,Zuba-Surma EK,Dawn B.Adult Bone Marrow Cell Therapy for Ischemic Heart Disease:Evidence and Insights From Randomized Controlled Trials.Circ Res 2015；117(6):558-575)。然而临床研究表明，间充质干细胞虽能一定程度通过旁分泌保护作用改善梗死后心功能，但效果并不显著。进一步研究表明，其发挥旁分泌保护作用的主要机制是通过分泌一种细胞外囊泡结构——外泌体(exosome)实现的(Makridakis M,Roubelakis MG,Vlahou A.Stem cells:insights into the secretome.Biochim Biophys Acta 2013；1834(11):2380-2384；Huang P,Tian X,Li Q,Yang Y.New  strategies for improving stem cell therapy in ischemic heart disease.Heart Fail Rev 2016；21(6):737-752；Lai RC,Arslan F,Lee MM,Sze NS,Choo A,Chen TS,Salto-Tellez M,Timmers L,Lee CN,El OR and others.Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury.Stem Cell Res 2010；4(3):214-222)。外泌体具有来源广、稳定、无免疫原性等优点，且BM-MSCs来源的外泌体(MSC-Exo)可改善心梗微环境，因此，有望成为新一代的心肌修复产品(Lamichhane TN,Sokic S,Schardt JS,Raiker RS,Lin JW,Jay SM.Emerging Roles for Extracellular Vesicles in Tissue Engineering and Regenerative Medicine.Tissue Engineering Part B:Reviews 2015；21(1):45-54)。
发明内容
本发明的一个目的在于提供一种高效间充质干细胞来源外泌体的制备方法。
本发明的研究发现，他汀类药物例如阿托伐他汀(Atorvastatin,ATV)预处理间充质干细胞，可显著提高间充质干细胞的抗凋亡能力和促归巢能力，制备出具有显著心梗微环境改善作用和高效心肌修复能力的干细胞来源外泌体。
一方面，本发明提供了一种间充质干细胞来源外泌体的制备方法，该方法包括：采用他汀类药物预处理间充质干细胞，并培养处理后的间充质干细胞以收集其分泌的外泌体。
根据本发明的具体实施方案，本发明的间充质干细胞来源外泌体的制备方法包括：
在间充质干细胞的培养基中加入他汀类药物预处理12-24小时后，更换细胞培养基为无外泌体的完全培养基继续培养；48小时后收集条件培养基并利用超速离心法分离得到经他汀类药物预处理间充质干细胞分泌的外泌体。
根据本发明的具体实施方案，本发明的间充质干细胞来源外泌体的制备方法中，所述超速离心法包括步骤：
收集条件培养基后，依次离心去除细胞、离心去除细胞碎片、高速离心去除大囊泡，然后超速离心收取沉淀并重悬后，再次超速离心获得外泌体；
在本发明的一优选具体实施方案中，收集条件培养基后，300g离心10min去除细胞；2000g离心20min去除细胞碎片；16500g高速离心30min去除大囊泡；120000g超速离心70min收取沉淀并重悬后，再次120000g超速离心70min获得外泌体。
根据本发明的具体实施方案，本发明的间充质干细胞来源外泌体的制备方法中， 所述他汀类药物包括阿托伐他汀。
根据本发明的具体实施方案，本发明的间充质干细胞来源外泌体的制备方法中，所述间充质干细胞包括骨髓间充质干细胞或脂肪间充质干细胞。
另一方面，本发明还提供了按照本发明所述方法制备得到的外泌体。
另一方面，本发明还提供了他汀类药物在制备促进间充质干细胞的抗凋亡能力和/或促归巢能力的制剂中的应用。
另一方面，本发明还提供了他汀类药物在制备促进间充质干细胞分泌具有心梗微环境改善作用和/或心肌修复能力的外泌体的制剂中的应用。
根据本发明的具体实施方案，本发明中，所述他汀类药物包括阿托伐他汀；优选地，利用1μM他汀类药物预处理间充质干细胞24小时。
根据本发明的具体实施方案，本发明中，所述间充质干细胞包括骨髓间充质干细胞或脂肪间充质干细胞。
在本发明的一个具体实施方案中，利用1μM ATV预处理BM-MSC 24小时可获得具有高效心肌修复和内皮保护功能的外泌体。
附图说明
图1A-图1C显示本发明实施例中间充质干细胞来源外泌体的鉴定结果。
图2A-图2D显示不同浓度ATV预处理间充质干细胞来源外泌体对内皮细胞的作用差异。
图3A-图3H显示ATV预处理间充质干细胞来源外泌体促进血管内皮细胞成管、迁移和存活检测结果。
图4A-图4F显示经ATV预处理间充质干细胞来源外泌体可显著改善大鼠心梗后心功能、减小梗死面积的检测结果。
图5A-图5K显示经ATV预处理间充质干细胞来源外泌体的保护作用与其上调lncRNAH19有关的检测结果。
具体实施方式
下面通过具体实施例进一步详细说明本发明的特点及所具有的技术效果，但本发明并不因此而受到任何限制。实施例中，各原始试剂材料均可商购获得，未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件，或按照仪器制造商所建议的条件。
实施例1
间充质干细胞来源外泌体的制备方法：利用差速贴壁法分离原代大鼠(Sprague-Dawley大鼠，60-80g)BM-MSCs并传代扩增至第3-4代备用。在BM-MSCs完全培养基(IMDM,Invitrogen,美国)中加入ATV预处理24小时后，更换细胞培养基为无外泌体的完全培养基(经超速离心18小时后得到的含10％FBSIMDM)继续培养。48小时后收取条件培养基并利用超速离心法分离得到经ATV预处理BM-MSCs分泌的外泌体(MSC ATV-Exo)。超速离心法具体步骤包括：收取条件培养基后，300g离心10min去除细胞；2000g离心20min去除细胞碎片；16500g高速离心30min去除大囊泡；120000g超速离心70min收取沉淀并重悬后，再次120000g超速离心70min获得外泌体。
对制备好的MSC ATV-Exo进行鉴定：包括电镜(HITACHI,H-600IV,日本)分析观察形态结构，NTA(Malvern Instruments,NanoSight,英国)分析外泌体的粒径分布以及通过Western Blot检测外泌体蛋白标志物。
比较不同浓度ATV预处理对MSC ATV-Exo功能的影响，筛选出最佳ATV预处理浓度。利用此最佳ATV浓度预处理制备的MSC ATV-Exo进行功能学评价，包括对血管内皮细胞的成管、迁移和抗凋亡作用的影响和心肌内注射后改善大鼠心梗后心功能、减小梗死面积的效果。最后进行分子生物学评价，即MSC ATV-Exo中lncRNA H19表达水平检测。
评价指标(研究结果)
利用超速离心法分离得到的MSC ATV-Exo在电镜下呈现球形或圆盘形，大小在100nm左右；NTA分析其粒径分布在30-150nm范围内；Western Blot检测显示MSC ATV-Exo高表达TSG101、Alix、CD63、CD81等外泌体蛋白标志物。ATV预处理后与无预处理的BM-MSC分泌的外泌体在形态、粒径分布和蛋白标志物上没有显著差异。具体结果可参见图1A-图1C，其中，图1A：电镜下观察间充质干细胞来源外泌体(MSC-Exo)的形态结构，呈球形或圆盘形，大小在100nm左右，经他汀预处理后形态不变；图1B：用NTA分析MSC-Exo的粒径分布，他汀预处理和未处理的MSC-Exo的粒径分布均在30-150nm范围内；图1C：外泌体的蛋白标志物鉴定，他汀预处理的MSC-Exo高表达TSG101、Alix、CD63、CD81等外泌体蛋白标志物。
对通过不同浓度ATV(0.01、0.1、1、10μM)预处理所得的MSC ATV-Exo进行功能学分析，发现利用1μM ATV预处理得到的MSC ATV-Exo促进内皮细胞成管和迁移的作用最为显著。具体结果可参见图2A-图2D。其中，图2A-图2B：不同浓度ATV(0.01、0.1、1、10μM)预处理间充质干细胞后提取的外泌体对内皮细胞成管的作用差异比较，其中1μMATV预处理后效果最佳(图2B)；图2C-图2D：不同浓度ATV预处理间充质干细胞后提取的外泌体对内皮细胞迁移的作用差异比较，其中1μM ATV预处理后效果最佳(图2D)。
与未经ATV预处理的MSC-Exo相比，MSC ATV-Exo可显著促进血管内皮细胞的成管和迁移，并能够促进缺氧无血清条件下内皮细胞的存活和抗凋亡作用。具体可参见图3A-图3H，其中，图3A-图3B：成管试验，与对照组相比，经ATV预处理间充质干细胞来源外泌体(MSC ATV-Exo)显著促进血管内皮细胞成管；图3C-图3D：划痕试验，与对照组相比，MSC ATV-Exo显著促进血管内皮细胞迁移；图3E-图3F：流式细胞学检测，与对照组相比，MSC ATV-Exo显著促进血管内皮细胞在缺氧无血清条件下的存活；图3G-图3H：Hoechst 33342染色，与对照组相比，MSC ATV-Exo显著减少血管内皮细胞在缺氧无血清条件下的凋亡。
与未经ATV预处理的MSC-Exo相比，MSC ATV-Exo心肌内注射后可显著改善大鼠心梗后心功能、减小梗死面积。具体可参见图4A-图4F，其中，图4A-图4B：经ATV预处理间充质干细胞来源外泌体(MSC ATV-Exo)移植显著改善心梗大鼠心功能；图4C-图4D：Masson染色显示MSC ATV-Exo移植显著减小大鼠心梗面积；图4E-图4F：天狼星红染色提示MSC ATV-Exo移植显著减小大鼠心梗局部胶原沉积。
与MSC-Exo相比，MSC ATV-Exo高表达lncRNA H19，达到10倍以上。利用小干扰RNA敲低经ATV预处理的MSC中lncRNA H19的表达水平再提取其分泌的外泌体(MSC ATV(Si)-Exo)则上述保护作用消除，说明lncRNA H19与MSC ATV-Exo高效的内皮细胞保护作用、心功能改善以及缩小梗死面积的作用有关。具体可参见图5A-图5K，其中，图5A-图5B：经ATV预处理间充质干细胞来源外泌体(MSC ATV-Exo)高表达lncRNA H19，利用小干扰RNA敲低后的外泌体(MSC ATV(Si)-Exo)中lncRNA H19表达水平显著下降；图5C-图5H：与MSC ATV-Exo相比，MSC ATV(Si)-Exo的内皮保护作用减弱；图5I-图5K：与MSC ATV-Exo相比，MSC ATV(Si)-Exo的改善梗死后心功能、心肌修复的作用减弱。
结论：利用1μM ATV预处理BM-MSC 24小时可获得具有高效内皮保护和心肌修复功能的外泌体，其机制与上调外泌体中lncRNAH19水平有关。

Claims (10)

  1. 一种间充质干细胞来源外泌体的制备方法，该方法包括：采用他汀类药物预处理间充质干细胞，并培养处理后的间充质干细胞以收集其分泌的外泌体。
  2. 根据权利要求1所述的方法，该方法包括：
    在间充质干细胞的培养基中加入他汀类药物预处理12-24小时后，更换细胞培养基为无外泌体的完全培养基继续培养；48小时后收集条件培养基并利用超速离心法分离得到经他汀类药物预处理间充质干细胞分泌的外泌体。
  3. 根据权利要求1或2所述的方法，其中，所述超速离心法包括步骤：
    收集条件培养基后，300g离心10min去除细胞；2000g离心20min去除细胞碎片；16500g高速离心30min去除大囊泡；120000g超速离心70min收取沉淀并重悬后，再次120000g超速离心70min获得外泌体。
  4. 根据权利要求1或2所述的方法，其中，所述他汀类药物包括阿托伐他汀。
  5. 根据权利要求1或2所述的方法，其中，所述间充质干细胞包括骨髓间充质干细胞或脂肪间充质干细胞。
  6. 按照权利要求1～5任一项所述方法制备得到的外泌体。
  7. 他汀类药物在制备促进间充质干细胞的抗凋亡能力和/或促归巢能力的制剂中的应用。
  8. 他汀类药物在制备促进间充质干细胞分泌具有心梗微环境改善作用和/或心肌修复能力的外泌体的制剂中的应用。
  9. 根据权利要求7或8所述的应用，其中，所述他汀类药物包括阿托伐他汀；优选地，利用1μM他汀类药物预处理间充质干细胞24小时。
  10. 根据权利要求7或8所述的应用，其中，所述间充质干细胞包括骨髓间充质干细胞或脂肪间充质干细胞。
PCT/CN2018/091843 2018-06-19 2018-06-19 基于药物预处理的间充质干细胞来源外泌体的制备方法 Ceased WO2019241910A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2019554538A JP6825182B2 (ja) 2018-06-19 2018-06-19 薬剤前処理による間葉系幹細胞由来エクソソームの調製方法
KR1020197033974A KR102235141B1 (ko) 2018-06-19 2018-06-19 약물 전처리에 기초한 간엽 줄기세포 유래 엑소좀 제조방법
PCT/CN2018/091843 WO2019241910A1 (zh) 2018-06-19 2018-06-19 基于药物预处理的间充质干细胞来源外泌体的制备方法
EP18923225.9A EP3663394B1 (en) 2018-06-19 2018-06-19 Method for preparing mesenchymal stem cell-derived exosomes on basis of drug pretreatment
US16/833,405 US20200224169A1 (en) 2018-06-19 2020-03-27 Preparation method of mesenchymal stem cell-derived exosomes based on drug pretreatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/091843 WO2019241910A1 (zh) 2018-06-19 2018-06-19 基于药物预处理的间充质干细胞来源外泌体的制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/833,405 Continuation-In-Part US20200224169A1 (en) 2018-06-19 2020-03-27 Preparation method of mesenchymal stem cell-derived exosomes based on drug pretreatment

Publications (1)

Publication Number Publication Date
WO2019241910A1 true WO2019241910A1 (zh) 2019-12-26

Family

ID=68982528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/091843 Ceased WO2019241910A1 (zh) 2018-06-19 2018-06-19 基于药物预处理的间充质干细胞来源外泌体的制备方法

Country Status (5)

Country Link
US (1) US20200224169A1 (zh)
EP (1) EP3663394B1 (zh)
JP (1) JP6825182B2 (zh)
KR (1) KR102235141B1 (zh)
WO (1) WO2019241910A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471650A (zh) * 2020-04-14 2020-07-31 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种人脐带间充质干细胞来源的外泌体、鉴定方法及应用
CN111925983A (zh) * 2020-08-14 2020-11-13 福建医科大学附属协和医院 一种用于治疗心肌梗死的高表达il-10的人脂肪间充质干细胞外泌体的制备方法
CN111944747A (zh) * 2020-08-14 2020-11-17 福建医科大学附属协和医院 一种用于治疗心肌梗死的人脂肪间充质干细胞外泌体及其用途
JP2022531846A (ja) * 2020-05-25 2022-07-12 シーケイ－エクソジーン カンパニー リミテッド 間葉系幹細胞由来のエキソソーム生産方法およびこれから製造された培養液
JP2023528083A (ja) * 2020-07-29 2023-07-03 プレクソジェン インコーポレイテッド 幹細胞由来エクソソームを含む組成物及びその製造方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112359013A (zh) * 2020-11-17 2021-02-12 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞外泌体的制备方法和应用
JP7598150B2 (ja) 2022-03-30 2024-12-11 株式会社山田養蜂場本社 エクソソーム分泌促進剤
CN117305233B (zh) * 2022-06-14 2024-07-05 北科芯(北京)干细胞医学研究院有限公司 骨髓间充质干细胞的外泌体、体外培养方法以及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129356A (zh) * 2007-08-01 2008-02-27 中国医学科学院阜外心血管病医院 洛伐他汀在制备抑制骨髓间充质干细胞凋亡药物上的应用
CN106282107A (zh) * 2016-08-30 2017-01-04 章毅 人胎盘间充质干细胞源分离外泌体的方法及其应用
CN107137700A (zh) * 2017-04-27 2017-09-08 张国瑜 一种基于干细胞源外泌体的组合物及其在制备治疗心肌梗死的药物中的应用
CN108728410A (zh) * 2018-06-19 2018-11-02 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072816B2 (en) * 2006-01-18 2015-07-07 Cormatrix Cardiovascular, Inc. Composition for modulating inflammation of cardiovascular tissue
EP2756847A1 (en) * 2011-09-13 2014-07-23 Takahiro Ochiya Pharmaceutical product for preventing or treating alzheimer's disease
US20170252379A1 (en) * 2014-10-09 2017-09-07 Anthrogenesis Corporation Placenta-derived adherent cell exosomes and uses thereof
EP3777890A1 (en) * 2014-11-10 2021-02-17 Masaaki II Stem cells containing statin-encapsulated nanoparticles
TWI601741B (zh) * 2016-07-11 2017-10-11 財團法人國家衛生研究院 利用前列腺素受體ｅｐ４－拮抗劑誘導幹細胞製造含有高囊泡含物之外泌體囊泡的方法及其應用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101129356A (zh) * 2007-08-01 2008-02-27 中国医学科学院阜外心血管病医院 洛伐他汀在制备抑制骨髓间充质干细胞凋亡药物上的应用
CN106282107A (zh) * 2016-08-30 2017-01-04 章毅 人胎盘间充质干细胞源分离外泌体的方法及其应用
CN107137700A (zh) * 2017-04-27 2017-09-08 张国瑜 一种基于干细胞源外泌体的组合物及其在制备治疗心肌梗死的药物中的应用
CN108728410A (zh) * 2018-06-19 2018-11-02 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AFZAL MRSAMANTA ASHAH ZIJEEVANANTHAM VABDEL-LATIF AZUBA-SURMA EKDAWN B: "Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials", CIRC RES, vol. 117, no. 6, 2015, pages 558 - 575
COLLABORATORS GCOD: "Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016", THE LANCET, vol. 390, no. 10100, 2017, pages 1151 - 1210
COLLABORATORS GM: "Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016", THE LANCET, vol. 390, no. 10100, 2017, pages 1084 - 1150
FISHER SADOREE CMATHUR AMARTIN-RENDON E: "Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure", CIRCULATION RESEARCH, vol. 116, no. 8, 2015, pages 1361 - 1377
HUANG PTIAN XLI QYANG Y: "New strategies for improving stem cell therapy in ischemic heart disease", HEART FAIL REV, vol. 21, no. 6, 2016, pages 737 - 752, XP036085165, DOI: 10.1007/s10741-016-9576-1
LAI RCARSLAN FLEE MMSZE NSCHOO ACHEN TSSALTO-TELLEZ MTIMMERS LLEE CNEL OR: "Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury", STEM CELL RES, vol. 4, no. 3, 2010, pages 214 - 222, XP055555858, DOI: 10.1016/j.scr.2009.12.003
LAMICHHANE TNSOKIC SSCHARDT JSRAIKER RSLIN JWJAY SM: "Emerging Roles for Extracellular Vesicles in Tissue Engineering and Regenerative Medicine", TISSUE ENGINEERING PART B: REVIEWS, vol. 21, no. 1, 2015, pages 45 - 54
MAKRIDAKIS MROUBELAKIS MGVLAHOU A: "Stem cells: insights into the secretome", BIOCHIM BIOPHYS ACTA, vol. 1834, no. 11, 2013, pages 2380 - 2384, XP028726666, DOI: 10.1016/j.bbapap.2013.01.032
ORLIC DKAJSTURA JCHIMENTI SJAKONIUK IANDERSON SMLI BPICKEL JMCKAY RNADAL-GINARD BBODINE DM: "Bone marrow cells regenerate infarcted myocardium", NATURE, vol. 410, no. 6829, 2001, pages 701 - 705, XP002965971, DOI: 10.1038/35070587
See also references of EP3663394A4

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471650A (zh) * 2020-04-14 2020-07-31 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种人脐带间充质干细胞来源的外泌体、鉴定方法及应用
CN111471650B (zh) * 2020-04-14 2021-07-27 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种人脐带间充质干细胞来源的外泌体、鉴定方法及应用
JP2022531846A (ja) * 2020-05-25 2022-07-12 シーケイ－エクソジーン カンパニー リミテッド 間葉系幹細胞由来のエキソソーム生産方法およびこれから製造された培養液
JP7449590B2 (ja) 2020-05-25 2024-03-14 シーケイ－エクソジーン カンパニー リミテッド 間葉系幹細胞由来のエキソソーム生産方法およびこれから製造された培養液
JP2023528083A (ja) * 2020-07-29 2023-07-03 プレクソジェン インコーポレイテッド 幹細胞由来エクソソームを含む組成物及びその製造方法
JP7568239B2 (ja) 2020-07-29 2024-10-16 プレクソジェン インコーポレイテッド 幹細胞由来エクソソームを含む組成物及びその製造方法
CN111925983A (zh) * 2020-08-14 2020-11-13 福建医科大学附属协和医院 一种用于治疗心肌梗死的高表达il-10的人脂肪间充质干细胞外泌体的制备方法
CN111944747A (zh) * 2020-08-14 2020-11-17 福建医科大学附属协和医院 一种用于治疗心肌梗死的人脂肪间充质干细胞外泌体及其用途

Also Published As

Publication number Publication date
EP3663394A4 (en) 2021-02-24
KR102235141B1 (ko) 2021-04-05
EP3663394A1 (en) 2020-06-10
JP6825182B2 (ja) 2021-02-03
EP3663394B1 (en) 2022-10-05
US20200224169A1 (en) 2020-07-16
JP2020522996A (ja) 2020-08-06
KR20200002930A (ko) 2020-01-08

Similar Documents

Publication Publication Date Title
KR102235141B1 (ko) 약물 전처리에 기초한 간엽 줄기세포 유래 엑소좀 제조방법
CN108728410B (zh) 基于药物预处理的间充质干细胞来源外泌体的制备方法
Shi et al. Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury
Hu et al. Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells
Kervadec et al. Cardiovascular progenitor–derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure
JP5371445B2 (ja) 脂肪組織由来細胞を培養する方法及びその使用
CN101642469B (zh) 脐带华通胶来源的间充质干细胞在急性心肌梗死细胞移植治疗中的应用
Wu et al. Cardiac potential of stem cells from whole human umbilical cord tissue
Tsao et al. Mesenchymal stem cell derived exosomes: a new hope for the treatment of cardiovascular disease?
Bian et al. Development of a KLD-12 polypeptide/TGF-β1-tissue scaffold promoting the differentiation of mesenchymal stem cell into nucleus pulposus-like cells for treatment of intervertebral disc degeneration
JP2023513395A (ja) 小胞及びその使用
Chong Cell therapy for left ventricular dysfunction: an overview for cardiac clinicians
CN104694466A (zh) 间充质干细胞来源的胞外体制备及在急性肺损伤中的应用
CN113373112B (zh) 基于通心络预处理的间充质干细胞来源外泌体及其制备方法
Mendelson et al. Mesenchymal stromal cells lower platelet activation and assist in platelet formation in vitro
Li et al. Isolation of swine bone marrow lin-/CD45-/CD133+ cells and cardio-protective effects of its exosomes
CN106606512B (zh) 一种用于治疗心肌梗死的混合细胞制剂及制备方法与应用
CN120738111A (zh) 获得诱导性平滑肌细胞的方法
CN115212232A (zh) 间充质干细胞来源的外泌体治疗脑卒中的方法和组合物
Hua et al. Cell transplantation into ischemic myocardium using mesenchymal stem cells transfected by vascular endothelial growth factor
CN115386542B (zh) 工程化的鹿茸干细胞外泌体和制备方法、及在骨肉瘤治疗中的应用
CN107058225B (zh) 一种复合诱导培养基以及采用该培养基诱导脐带间充质干细胞成神经元样细胞的方法
Şanlı et al. Current Advances in Stem Cell-Based Therapies: Adult Stem Cell Applications
Zhao et al. Advances in the research of mesenchymal stromal cells in the treatment of maxillofacial neurological disorders and the promotion of facial nerve regeneration
CN102559591A (zh) 一种提取肺间充质干细胞的方法

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2019554538

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197033974

Country of ref document: KR

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18923225

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018923225

Country of ref document: EP

Effective date: 20200303

NENP Non-entry into the national phase

Ref country code: DE